REPCF - RepliCel Life Sciences Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2863
-0.0039 (-1.34%)
At close: 2:58PM EDT
Stock chart is not supported by your current browser
Previous Close0.2902
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume13,665
Market Cap6.139M
Beta-0.44
PE Ratio (TTM)N/A
EPS (TTM)-0.1940
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO
    CNW Group2 months ago

    RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO

    VANCOUVER and NINGBO , Zhejiang Province , China , May 2, 2018 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it now has a new Binding Term Sheet (the "Term Sheet") with YOFOTO ( China ) Health Industry Co. Ltd. ("YOFOTO") which both parties believe represents a stronger deal for both sides and positions them to finalize the transaction in the very near-term.

  • PR Newswire5 months ago

    RepliCel CEO Provides 2018 Shareholder Update

    VANCOUVER, Jan. 25, 2018 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its President and CEO, Mr. R. Lee Buckler. The Company had a very successful 2017, which has only paved the way for a successful year as we enter into 2018. Looking back over the past 24 months, 2016 was about restructuring and refinancing the Company,  2017 was about delivering promised clinical and injector milestones, and now 2018 is about expansion.

  • RepliCel CEO Provides 2018 Shareholder Update
    CNW Group5 months ago

    RepliCel CEO Provides 2018 Shareholder Update

    RepliCel CEO Provides 2018 Shareholder Update

  • PR Newswire5 months ago

    RepliCel Life Sciences Lands Commitment for Key Investment Partnership

    VANCOUVER and NINGBO, Zhejiang Province, China, Jan. 16, 2018 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has signed a Binding Term Sheet (the "Term Sheet") with YOFOTO (China) Health Industry Co. Ltd. ("YOFOTO") to form a strategic partnership (the "Transaction") in Greater China (Mainland China, Hong Kong, Macau, and Taiwan) (the "Territory").

  • RepliCel Life Sciences Lands Commitment for Key Investment Partnership
    CNW Group5 months ago

    RepliCel Life Sciences Lands Commitment for Key Investment Partnership

    RepliCel Life Sciences Lands Commitment for Key Investment Partnership

  • Marketwired8 months ago

    Streetwise Reports Interviews CJ Partners' Colin Lee Novick Who Says Japan is Fertile Ground for Biotech Deals

    Japan and the United States are hotspots for companies that are looking to license-out exciting regenerative medicine technology, says Colin Lee Novick, managing director of CJ PARTNERS. In this interview ...

  • PR Newswire9 months ago

    RepliCel Retains Hybrid Financial for Investor Relations

    VANCOUVER, Sept. 22, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has retained Hybrid Financial Inc. ("Hybrid") to provide certain investor relations services (the "Services") to the Company, commencing September 26, 2017. Under the terms of Hybrid's engagement (the "Engagement"), RepliCel has agreed to pay Hybrid a monthly retainer of CAD$15,000 for an initial term of six months, with such retainer payable upon completion of RepliCel's next financing. Upon completion of the initial six-month term, RepliCel may extend the term of the Engagement on a month-to-month basis.

  • RepliCel Retains Hybrid Financial for Investor Relations
    CNW Group9 months ago

    RepliCel Retains Hybrid Financial for Investor Relations

    RepliCel Retains Hybrid Financial for Investor Relations

  • PR Newswire9 months ago

    RepliCel's Partnership Initiatives Mature into Licensing Negotiations

    VANCOUVER, Sept. 13, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it anticipates maturing discussions will lead to one or more new partnership agreements in the near-term. "The release of our positive clinical data earlier this year and the recent unveiling of our next-generation dermal injector prototypes have aggressively bolstered partnership negotiations," says RepliCel President and CEO, R. Lee Buckler. "We remain confident of our ability to execute one or more partnerships for the dermal injector on our way to it being CE-marked by mid-2018, and have also generated significant partnership interest in our biologic assets among strong regional players.

  • CNW Group9 months ago

    RepliCel's Partnership Initiatives Mature into Licensing Negotiations

    RepliCel's Partnership Initiatives Mature into Licensing Negotiations

  • PR Newswire9 months ago

    RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector

    VANCOUVER, Sept. 7, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce the timely arrival of its RCI-02 prototypes, which are now ready to be showcased to potential end users and licensing partners. With functioning prototypes in-hand, RepliCel is now engaging with key opinion leaders and clinical dermatologists to solicit feedback critically important to aligning successful early adoption of the device, design clinical studies demonstrating its advantages in select applications, and position the Company for an anticipated successful launch of an approved next-generation dermal injector in the European market next year. "As a practicing dermatologist and a co-founder of RepliCel, I am thrilled to see the functioning prototypes.

  • RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector
    CNW Group9 months ago

    RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector

    RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector

  • Marketwired10 months ago

    Streetwise Reports Examines Analyst's View that Cell Therapy Company's Move Decreases Risk

    A regenerative medicine company has signed on to the ThawSTAR Early Adopter Program, a move analyst Douglas Loe of Echelon Wealth Partners terms "positive logistically" to development risk.Included ...

  • Business Wire10 months ago

    RepliCel Life Sciences Joins MedCision’s ThawSTAR® Early Adopter Program

    MedCision, LLC, the world leader in next-generation automated cell thawing for advanced therapies, and RepliCel Life Sciences, Inc.  , a regenerative medicine company, today announced that RepliCel has joined MedCision’s ThawSTAR® Early Adopter Program, a novel program that helps companies and investigators de-risk thawing of cell therapies in early stage clinical trials through to commercialization ...

  • PR Newswire10 months ago

    Prominent Skin Aging Researcher Provides Insights into RepliCel's Clinical Data

    Q: In your center, a phase 1 trial has been performed to assess the safety of an autologous cell product against skin aging.  Can you tell us why, in your opinion, the data from this trial suggests to you that such a cell treatment has the potential to treat signs of skin aging? Prof. Dr. med Jean Krutmann: I am personally very interested in this approach because it represents, to the best of my knowledge, the first cell-based treatment option for skin aging.

  • Prominent Skin Aging Researcher Provides Insights into RepliCel's Clinical Data
    CNW Group10 months ago

    Prominent Skin Aging Researcher Provides Insights into RepliCel's Clinical Data

    Prominent Skin Aging Researcher Provides Insights into RepliCel's Clinical Data